Abstract:The current review described a 55-year woman using 28 months to finish her surgery-based radiation-free multimodality treatment journey to fight International Federation of Gynaecology & Obstetrics (FIGO) 2018 clinical stage IIA2 (cT2aN0M0) squamous cell carcinoma (SCC) of the cervix. She received six cycles of perioperative adjuvant therapy, including three cycles of neoadjuvant therapy (NAT) and three cycles of postoperative adjuvant therapy by using combination of dose-dense chemotherapy (CT, weekly paclitaxel 80 mg/m2+triweekly cisplatin 40 mg/m2), immunotherapy (IO, triweekly pembrolizumab 200 mg) and half-dose anti-angiogenic agent (triweekly bevacizumab 7.5 mg/kg) plus interval radical surgery (radical hysterectomy + bilateral salpingo-oophorectomy + bilateral pelvic lymph node dissection + para-aortic lymph node sampling) and following maintenance therapy with monthly 22 cycles of half-dose of IO (pembrolizumab 100 mg) and concomitant 4 cycles of single-agent CT (paclitaxel 175 mg/m2) and 18 cycles of half-dose anti-angiogenic agent (bevacizumab 7.5 mg/kg). During the cervical SCC fighting journey, two unwanted adverse events (AEs) occurred. One was pseudo-progressive disease during the NAT treatment and pathology-confirmed upgrading FIGO stage IIIC1p (ypT2a1N1M0) after radical surgery and the other was the occurrence of hypothyroidism during the post operative adjuvant therapy. Based on this case we presented, we review the recent trend in the management of women with locally advanced cervical cancer (LACC) using the radiation-free but surgery-based multimodality strategy and highlight the strengths and limitations about perioperative adjuvant therapy with dose-dense CT + IO + half-dose anti-angiogenic agent and maintenance treatment of half-dose IO combining with short-term single agent CT and following long-term half-dose anti-angiogenic agent. All underscore the possibility that women with LACC have an opportunity to receive surgery-based RT-free multi-modality strategy to manage their diseases with satisfactory results. Additionally, the evolving role of IO plus CT with/without anti-angiogenic agent functioning as either primary treatment or adjuvant therapy for the treatment of advanced CC has been in process continuously. Moreover, the patient's positive response to IO, pembrolizumab as an example, both during the primary and maintenance therapy, highlights the importance of integrating IO into CT regimens for CC, especially in cases where conventional therapies, RT as an example, are insufficient or who do not want to receive RT-based treatment. The sustained disease-free status of the patient over several years reinforces the potential of IO to significantly increase long-term survival outcomes in CC patients, particularly for those with LACC.

Multi-modality Therapies for Advanced Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT): Three Case Reports and Literature Review

Immunotherapy Combined with Targeted Therapy in Advanced Small Cell Carcinoma of the Ovary of Hypercalcemic Type: A Case of Overall Survival Lasting for over 5 Years

An In-Depth Look at Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT): Clinical Implications from Recent Molecular Findings

Clinical characteristics and status of treatment of small-cell carcinoma of the ovary, hypercalcemic type in the Chinese population: a meta-analysis

EP355/#365 Multiomics Profiling of Chinese Patients with Small Cell Carcinoma of the Ovary, Hypercalcemic Type

Ovarian Small-Cell Carcinoma Hypercalcemic Type Successfully Treated: a Case Report and Literature Review

Case report: Successful treatment of a rare HER2-positive advanced breast squamous cell carcinoma

Ovarian small-cell carcinoma hypercalcemic type successfully treated: a case report and literature review.

MR imaging diagnosis of small-cell carcinoma of the ovary, hypercalcemic type: A case report and literature review

Primary ovarian small cell carcinoma of pulmonary type with coexisting endometrial carcinoma in a breast cancer patient receiving tamoxifen: A case report and literature review

Establishment and Characterization of a Novel Cell Line (SCCOHT-CH-1) and PDX Models Derived from Chinese Patients of Small Cell Ovarian Carcinoma of the Hypercalcemic Type

Where We Stand and What Lies Ahead

Clinicopathological and molecular features of tubo-ovarian carcinosarcomas: a series of 51 cases

The surgical, histopathological characteristics, and survival outcome of ovarian clear cell carcinoma: a retrospective case series sharing the experience of a tertiary cancer centre

Surgery-based radiation-free multimodality treatment for locally advanced cervical cancer

Clinicopathologic feature and treatment progress of high-grade ovarian neuroendocrine tumors

Comprehensive characterization of genomic features and clinical outcomes following targeted therapy and secondary cytoreductive surgery in OCCC: a single center experience

Metastatic Upper Thoracic Intramedullary Spinal Cord Tumor of Ovarian Adenocarcinoma: A Rare Case Report and Literature Review

Case Report: Management of Recurrent Ovarian Squamous Cell Carcinoma With PD-1 Inhibitor

Squamous cell carcinoma of the cervix associated with choriocarcinomatous differentiation: a case report and review of the literature